Patent 7101869 was granted and assigned to Pfizer on September, 2006 by the United States Patent and Trademark Office.
Novel compounds according to the formulaand pharmaceutically acceptable salts, solvates, or hydrates thereof; whereineach occurrence of A is independently selected from CH or N;X is selected from the group consisting of —CH2—, —O—, —NH—, (C1-C6)alkylamino-, (C1-C6)alkylaminocarbonylamino-, (C1-C6)alkylcarbonylamino-, (C1-C6)alkylsulfonylamino-, phenylsulfonylamino-, carbonyl, —NH—C(O)—, —N(C1-C6)alkyl-C(O)—, —S(O)y— where y is 0, 1 or 2, and;n in —(CH2)n— is 1, 2 or 3; andR1, R2, and R3 are as described herein; pharmaceutical compositions that including these compounds, and methods for the treatment of autoimmune disease, inflammation, allergy, transplant rejection, and other circumstances where administration of an immunosuppressive agent is of therapeutic benefit.